ABT vs BSX
Abbott Laboratories and Boston Scientific, both Healthcare
Abbott Laboratories is the larger company at $154B against $67B. On trailing earnings BSX is the cheaper of the two at a P/E of 17.3 against 27.8, a gap that is only a bargain if the two are growing at similar rates. Over the past year ABT returned -25% against -56% for BSX. The RyuScore puts BSX ahead, 65 against 60 out of 100.
| Figure | ABT | BSX |
|---|---|---|
| Last close | $99.59 | $42.74 |
| Market cap | $154B | $67B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.8 | 17.3 |
| Dividend yield | 2.4% | n/a |
| 1-year return | -25% | -56% |
| 5-year return | -14% | -3.3% |
| RyuScoresector-relative, 1–10 | 60/100 | 65/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Abbott Laboratories
Revenue of $11B in Q1 2026, net income $1.1B. Its largest reported line is Nutritional Products, 41% of the disclosed total.
Boston Scientific
Revenue of $5.4B in Q2 2026, net income $905M. Its largest reported line is Electrophysiology EP, 18% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.